Chemistry:Maitansine
From HandWiki
| |
| Names | |
|---|---|
| Other names
Maytansin
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
PubChem CID
|
|
| UNII | |
| |
| |
| Properties | |
| C34H46ClN3O10 | |
| Molar mass | 692.20 g/mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
 verify (what is   ?)
| |
| Infobox references | |
Tracking categories (test):
Maitansine (INN), or maytansine (USAN), is a cytotoxic agent. It inhibits the assembly of microtubules by binding to tubulin at the rhizoxin binding site.[1]
It is a macrolide of the ansamycin type and can be isolated from plants of the genus Maytenus.[1]
Maytansinoids
Derivatives of maitansine are known as maytansinoids.[2][3] Some are being investigated as the cytotoxic component of antibody-drug conjugates for cancer treatment,[4] and the antibody-drug conjugate trastuzumab emtansine is an approved drug for the treatment of certain kinds of breast cancer in the EU and in the US.[5][6]
Examples of maytansinoids are:
- Ansamitocin[2]
- Mertansine / emtansine (DM1)
- Ravtansine / soravtansine (DM4)
See also
- ImmunoGen, developer of maytansinoid based drugs
References
- ↑ 1.0 1.1 National Cancer Institute: Definition of Maytansine
- ↑ 2.0 2.1 Yu, T.-W.; Bai, L; Clade, D; Hoffmann, D; Toelzer, S; Trinh, KQ; Xu, J; Moss, SJ et al. (2002). "The biosynthetic gene cluster of the maytansinoid antitumor agent ansamitocin from Actinosynnemapretiosum". Proceedings of the National Academy of Sciences 99 (12): 7968–7973. doi:10.1073/pnas.092697199. PMID 12060743. Bibcode: 2002PNAS...99.7968Y.
- ↑ Lopus, M; Oroudjev, E; Wilson, L; Wilhelm, S; Widdison, W; Chari, R; Jordan, MA (2010). "Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules". Mol Cancer Ther 9 (10): 2689–99. doi:10.1158/1535-7163.MCT-10-0644. PMID 20937594.
- ↑ Chari, RV et al. (January 1992). "Immunoconjugates containing novel maytansinoids: promising anticancer drugs.". Cancer Res. 52 (1): 127–31. PMID 1727373. http://cancerres.aacrjournals.org/content/52/1/127.full.pdf.
- ↑ "Kadcyla EPAR". 17 September 2018. https://www.ema.europa.eu/en/medicines/human/EPAR/kadcyla.
- ↑ "Drug Approval Package: ado-trastuzumab emtansine". 22 February 2013. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/125427Orig1s000TOC.cfm.
 |  |
